ASCO: Phase III ALEX study of Alectinib

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

Abstract No : 9518

Abstract Type : Poster Discussion Session

Indication : ALK+ NSCLC

Intervention : Alectinib (ALC) versus crizotinib (CRZ)

Company : F. Hoffman-La Roche Ltd

Technology : Small molecule


This is the first global randomized study of a 2nd generation ALK TKI to demonstrate a clinically meaningful improvement in OS vs CRZ in ALK+ NSCLC (5-year survival rate: 62.5%, ALC vs 45.5%, CRZ); longer FU is required as OS data remain immature.


Around 62.5% patients are still alive at 5 years on alectinib compared to 45.5% in first crizotinib (CRZ) in the global randomized study which will further strengthen the position of first line usage of alectinib


Roche presented long term data of alectinib from ALEX study in frontline advanced ALK+ NSCLC.

Refer to ALK positive NSCLC Market report for detailed Insights.